FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
A program developed by the Chicago Department of Public Health uses Twitter to help combat foodborne illness in the city.
An analysis of the 2010 National Health Interview Survey determined that physicians and dental health professionals are not telling all smokers they see to quit.
American adults are eating too little fish to meet current recommendations for fish-derived omega-3 fatty acids.
While diet and supplementation have not been shown to prevent mental illness, several supplements have been associated with symptom relief.
Latest Issues
$auto_registration$